NCOG-08. NEUROCOGNITIVE FUNCTIONING IN EORTC BRAIN TUMOR GROUP RANDOMIZED PHASE II TAVAREC TRIAL (EORTC 26091, NCT01164189) ON TEMOZOLOMIDE WITH OR WITHOUT BEVACIZUMAB in 1p/19q INTACT RECURRENT GRADE II AND III GLIOMAS
Martin Klein(Amsterdam University Medical Centers), Martin J. van den Bent(Erasmus MC Cancer Institute), Michael Weller(University Hospital of Zurich), Walter Taal(Heidelberg University), Filip De Vos(University Medical Center Utrecht), Thierry Gorlia(European Organisation for Research and Treatment of Cancer), Antje Wick(Heidelberg University), Tina Verschuere(KU Leuven), Paul Mulholland(University College London Hospitals NHS Foundation Trust), Martin Taphoorn(Leiden University Medical Center), Ahmed Idbaïh(Centre National de la Recherche Scientifique), Joanne Lewis(Freeman Hospital), Paul M. Clément(Universitair Ziekenhuis Leuven), Vassilis Golfinopoulos(Champalimaud Foundation), Jaap C. Reijneveld(Amsterdam UMC Location University of Amsterdam)
Cited by 0
Related Papers
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
|Neuro-Oncology|2020|1.1k